MUBADALA HEALTH AND G42 HEALTHCARE SIGN MOU TO BOOST UAE’S RESEARCH AND SCIENTIFIC CAPABILITIES

30

● MoU will enable sharing best practices and knowledge to support world-class healthcare standards

● Genetic counselling services and collaborations in the clinical and research domains to support the UAE and the region

Abu Dhabi, United Arab Emirates: G42 Healthcare, an Abu Dhabi-based leading healthcare technology company, and Mubadala Health, an integrated healthcare network dedicated to establishing the highest international standards of care in the UAE and the region, today announced the signing of a Memorandum of Understanding (MoU) to advance healthcare provision in the UAE.

The partnership between Mubadala Health and G42 Healthcare showcases commitment to the UAE’s healthcare vision through exchanging expertise and best practices, and the significant role this plays in strengthening the nation’s healthcare infrastructure.

In a continued effort to futureproof the health of nations, the partnership will enable both entities to collaborate on various clinical and screening programs, scientific projects and omics initiatives that will have a lasting impact on the population’s health.

Commenting on the partnership, Hasan Jasem Al Nowais, CEO of Mubadala Health, said: “In line with Mubadala Health’s strategic commitment to bring advanced healthcare to the region, we have long been focused on preventative healthcare. The collaboration with G42 Healthcare will help us to further uncover genetic links to chronic diseases. The partnership will enable us to offer our patients deep, targeted insights into specific areas of the genome to assess their risk of developing certain diseases, or to diagnose genetic conditions. We are confident that exchanging best practices and resources will support the establishment of a more connected healthcare system in the UAE.”

As trusted resources for healthcare providers and patients, Mubadala Health and G42 Healthcare are committed to driving improvement in care delivery in the region and have invested in state-of-the-art technologies.

Ashish Koshy, CEO of G42 Healthcare, said: “This is a significant partnership for the future of UAE’s healthcare ecosystem. As a forward-looking company, we are committed to uphold innovative collaborations and practices that steer the growth of the country’s healthcare infrastructure. As part of this crucial partnership, G42 Healthcare and Mubadala Health will help find innovative solutions to chronic diseases and create tailored healthcare strategies for patients. We encourage such partnerships with committed players in the UAE and beyond.”

As a leader in the UAE healthcare sector, Mubadala Health’s strength of clinical expertise and recognition as a trusted healthcare network will complement G42 Healthcare’s key offerings, such as its state-of-the-art laboratories, scientific, and research programs.

About G42 Healthcare:

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem.

At the forefront in the battle against COVID-19, we have established Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, supported UAE’s healthcare authorities on the national vaccination implementation, employed advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.

Beyond COVID-19 we have plans and R&D encompassing genomics, imaging and diagnostics, and digitization programs to support the health of future generations. At G42 Healthcare, our plans are large in scale and bold in ambition. We partner extensively with governments, leading international entities, scientists and researchers and the wider medical community who subscribe to our values and our mission as we develop solutions to future-proof the health of nations.

About Mubadala Health:

Mubadala Health is the integrated healthcare network of Mubadala Investment Company. Established in 2021, Mubadala Health operates, manages, and develops a portfolio of healthcare assets including: Cleveland Clinic Abu Dhabi, Healthpoint, Imperial College London Diabetes Centre (ICLDC), Amana Healthcare, National Reference Laboratory (NRL), Capital Health Screening Centre (CHSC), Abu Dhabi Telemedicine Centre (ADTC), Danat Al Emarat, HealthPlus Diabetes & Endocrinology Center, HealthPlus Family Clinics, HealthPlus Fertility, HealthPlus Women’s Health Center, Moorfields Eye Hospital Abu Dhabi, and a stake in Al Meswak Dental Clinics Group. With a vision to transform the regional healthcare landscape, Mubadala Health sets a new benchmark for the UAE and regional healthcare industry through its state-of-the-art facilities and world-class caregivers who strive to put patients first across its continuum of care. Innovation, research, and education are the foundational pillars of Mubadala Health, supporting the further development of a sustainable healthcare sector in line with the vision of Abu Dhabi and the region.